Deploying Modeling & Simulation to Enable Advanced Process Monitoring & Control

18th September 2023 | 10:00am EST / 7:00am PST / 3:00pm BST / 4:00pm CEST | Johannes Scheiblauer, Associate Scientific Fellow for Digital CMC at Takeda and Sean Bermingham, Head of Formulated Products at Siemens |WATCH FOR FREE

Several enabling technologies change the way we do pharmaceutical development: automation & digitalization, advanced analytical methods, modeling & simulation. But especially the latter are not silver bullets, and it is important to have a closer look why and when one might use them.

In this presentation, we focus on the real-time applications of modeling & simulation in the context of process monitoring & control: how to leverage the underlying technologies to better visualize current process data, improve process control decisions and anticipate future process trajectories.

We discuss factors and prerequisites supporting a successful and sustainable implementation, from the “digital maturity” of the processes over the necessary technical building blocks (like robotics & high-throughput experimentation) to aspects of people mindset and change management: what it means for an organization to embrace these new ways of work.

Presented by Johannes Scheiblauer, Associate Scientific Fellow for Digital CMC at Takeda

Johannes holds degrees in Physics and Biomedical Engineering with a major in Computational Biology from Technical University of Vienna. After having supported Takeda in various PAT & QbD projects as an external consultant, he joined the Pharmaceutical Sciences Team within Takeda R&D in May 2019. As Associate Scientific Fellow for Digital CMC, one of his responsibilities is – in close collaboration with the subject matter experts – the design and implementation of advanced process control & automation architectures. He is especially excited by the interdisciplinarity of this task, which he aspires to further extend around the imperatives of environmental sustainability. When away from work, Johannes enjoys spending time with family & friends and loves to both play and watch games of football or tennis.

Followed by Sean Bermingham, head of formulated products at Siemens

Sean joined Siemens Process Systems Engineering in 2000 and has been Head of SPSE’s Formulated Products business unit since 2009. Prior to this role, he was SPSE’s Global Head of Consulting. In his current role, he is responsible for strategic business development, software product development and services delivery for the pharma, food, consumer good, mining, specialty & agrochemical industries. Sean is a leading figure in the development and adoption of mechanistic model-based tools for increasing R&D efficiency and managing risk in areas ranging from clinical trials to tech transfer and operations. He is one of the founders of the Systems-based Pharmaceutics Alliance with Bayer, GSK, Lilly, Pfizer, Roche and Sanofi, and was the lead for the £20.4m ADDoPT “Digital Design” Project with partners including AZ, BMS, GSK & Pfizer. Sean is a Chemical Engineer with an MSc in Chemical Engineering and a PhD in crystallization from Delft University of Technology and an Executive MBA from Imperial College London.

Sponsored by Siemens gPROMS and gPROMS FormulatedProducts

About Siemens gPROMS

Siemens provides a family of technology-leading gPROMS modeling environments for digital process design, engineering and operations. These deploy deep process knowledge to accelerate process and product innovation, reduce the need for experimentation and pilots and design better, safer processes that lock in value over the asset lifetime – creating value at every step.

About Siemens gPROMS FormulatedProducts

Built on Siemens gPROMS® advanced process modelling platform, gPROMS FormulatedProducts helps organisations to bring high quality drugs to patients faster through the rapid configuration, calibration and deployment of science-based, data-calibrated digital process twins. The tool contains a suite of mechanistic and hybrid models of unit operations such as bioreactors, chromatography, membrane filtration, crystallization, spray drying and granulation – combined with in-vitro/vivo product performance models. Since 2013, the offering has been pioneering the emerging science of Systems-based Pharmaceutics with Bayer, Eli Lilly, GSK, Pfizer, Roche and Sanofi.” 

We will not sell your information to a third party. See our Privacy Policy